PL2561067T3 - Kompozycje RAAV-cyklazy guanylanowej i sposoby leczenia wrodzonej amaurozy-1 Lebera (LCA1) - Google Patents

Kompozycje RAAV-cyklazy guanylanowej i sposoby leczenia wrodzonej amaurozy-1 Lebera (LCA1)

Info

Publication number
PL2561067T3
PL2561067T3 PL11726973T PL11726973T PL2561067T3 PL 2561067 T3 PL2561067 T3 PL 2561067T3 PL 11726973 T PL11726973 T PL 11726973T PL 11726973 T PL11726973 T PL 11726973T PL 2561067 T3 PL2561067 T3 PL 2561067T3
Authority
PL
Poland
Prior art keywords
amaurose
lca1
leber
raav
congenital
Prior art date
Application number
PL11726973T
Other languages
English (en)
Inventor
Shannon Elizabeth Boye
William W. Hauswirth
Sanford Leon Boye
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of PL2561067T3 publication Critical patent/PL2561067T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01002—Guanylate cyclase (4.6.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PL11726973T 2010-04-23 2011-04-22 Kompozycje RAAV-cyklazy guanylanowej i sposoby leczenia wrodzonej amaurozy-1 Lebera (LCA1) PL2561067T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32752110P 2010-04-23 2010-04-23
PCT/US2011/033669 WO2011133933A2 (en) 2010-04-23 2011-04-22 Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
EP11726973.8A EP2561067B1 (en) 2010-04-23 2011-04-22 Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)

Publications (1)

Publication Number Publication Date
PL2561067T3 true PL2561067T3 (pl) 2019-05-31

Family

ID=44533055

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18198722T PL3486320T3 (pl) 2010-04-23 2011-04-22 Kompozycje RAAV-cyklazy guanylanowej i sposoby leczenia wrodzonej amaurozy-1 Lebera (LCA1)
PL11726973T PL2561067T3 (pl) 2010-04-23 2011-04-22 Kompozycje RAAV-cyklazy guanylanowej i sposoby leczenia wrodzonej amaurozy-1 Lebera (LCA1)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18198722T PL3486320T3 (pl) 2010-04-23 2011-04-22 Kompozycje RAAV-cyklazy guanylanowej i sposoby leczenia wrodzonej amaurozy-1 Lebera (LCA1)

Country Status (28)

Country Link
US (3) US9816108B2 (pl)
EP (3) EP2561067B1 (pl)
JP (4) JP5897549B2 (pl)
KR (3) KR20190060881A (pl)
CN (2) CN102918152B (pl)
AU (1) AU2011242527B2 (pl)
BR (1) BR112012026730A8 (pl)
CA (1) CA2796399C (pl)
CL (1) CL2012002969A1 (pl)
CO (1) CO6640236A2 (pl)
CY (1) CY1123008T1 (pl)
DK (2) DK2561067T3 (pl)
EA (2) EA202091105A1 (pl)
ES (2) ES2711256T3 (pl)
HR (1) HRP20190144T1 (pl)
HU (1) HUE041571T2 (pl)
IL (2) IL222651B (pl)
LT (1) LT2561067T (pl)
MX (1) MX351865B (pl)
NZ (1) NZ602897A (pl)
PL (2) PL3486320T3 (pl)
PT (2) PT3486320T (pl)
RS (1) RS58434B1 (pl)
SG (4) SG184876A1 (pl)
SI (1) SI2561067T1 (pl)
SM (1) SMT201900097T1 (pl)
TR (1) TR201901377T4 (pl)
WO (1) WO2011133933A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
WO2013075008A1 (en) 2011-11-16 2013-05-23 University Of Florida Research Foundation Inc. Aav dual vector systems for gene therapy
HUE051632T2 (hu) 2012-06-19 2021-03-29 Univ Florida Betegségek kezelésére szolgáló készítmények és eljárások
FR3008618A1 (fr) * 2013-07-19 2015-01-23 Univ Paris Curie Utilisation de composes pour restaurer la reponse a la lumiere des cellules de la retine
CA3209883A1 (en) 2013-07-22 2015-01-29 The Children's Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
EP3030665B9 (en) 2013-08-05 2023-10-04 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Recombinant aav-crumbs homologue composition and methods for treating lca-8 and progressive rp
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
HUE068603T2 (hu) 2015-06-23 2025-01-28 Childrens Hospital Philadelphia Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez
WO2017151823A1 (en) * 2016-03-01 2017-09-08 University Of Florida Research Foundation, Inc. Aav vectors for treatment of dominant retinitis pigmentosa
KR102526506B1 (ko) * 2016-07-08 2023-05-03 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물
CA3061955A1 (en) * 2017-05-05 2018-11-08 University Of Florida Research Foundation, Incorporated Compositions and methods for expressing otoferlin
AU2018323473B2 (en) 2017-08-28 2025-06-26 Editas Medicine, Inc. Methods and compositions for treating cone-rod retinal dystrophy
WO2019099696A1 (en) * 2017-11-15 2019-05-23 The Regents Of The University Of Michigan Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
US11845952B2 (en) 2018-02-07 2023-12-19 Nippon Medical School Foundation Adeno-associated virus vector
US11660353B2 (en) 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
CN119410637A (zh) 2018-04-27 2025-02-11 分贝治疗公司 肌球蛋白15启动子及其用途
SG11202100092QA (en) * 2018-07-11 2021-02-25 Cyclerion Therapeutics Inc USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
US12188041B2 (en) 2018-11-01 2025-01-07 University Of Florida Research Foundation, Incorporated Codon optimized otoferlin AAV dual vector gene therapy
WO2020154535A1 (en) * 2019-01-23 2020-07-30 University Of Florida Research Foundation, Incorporated Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
CN119320772A (zh) 2019-02-08 2025-01-17 分贝治疗公司 肌球蛋白15启动子及其用途
EP3921032A4 (en) 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS
EP3924470A4 (en) 2019-02-15 2022-12-14 Exhaura, Ltd. DUAL LEUCINE ZIPPER KINASE INHIBITORS FOR GENE THERAPY
AU2021247172A1 (en) 2020-04-01 2022-09-15 University Of Florida Research Foundation, Incorporated Dual AAV-MY07A vectors with improved safety for the treatment of USH1B
WO2021211641A2 (en) * 2020-04-14 2021-10-21 University Of Florida Researchfoundation, Incorporated Enhancing aav-mediated delivery and transduction with polyvinyl alcohol
WO2021211614A1 (en) 2020-04-14 2021-10-21 University Of Florida Research Foundation, Incorporated Aav-based gene therapies for treatment of autoimmune diseases
JP2024016295A (ja) * 2020-11-30 2024-02-07 タカラバイオ株式会社 二価の陽イオンを利用した非エンベロープウイルスの製造方法
CN112852976B (zh) * 2021-03-17 2023-10-31 湖北省农业科学院畜牧兽医研究所 蛋鸡ncs1基因中与后期产蛋性状相关的分子标记及其应用
KR20240055728A (ko) * 2021-07-14 2024-04-29 메이라지티엑스 유케이 Ii 리미티드 Retgc 유전자 요법

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0451221B1 (en) 1989-08-31 1994-10-12 City Of Hope Chimeric dna-rna catalytic sequences
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
AU6505690A (en) 1989-09-26 1991-04-28 Richard R Behringer Erythroid-specific gene expression system
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US6365730B1 (en) 1990-06-19 2002-04-02 Gene Shears Pty. Limited DNA-Armed ribozymes and minizymes
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
JP3257675B2 (ja) 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． 修飾リボザイム
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
DK0620849T3 (da) 1992-01-07 2003-10-20 Elan Pharm Inc Transgene dyremodeller for Alzheimer's sygdom
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5639940A (en) 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
US5789655A (en) 1994-05-13 1998-08-04 The Regents Of The University Of California Transgenic animals expressing artificial epitope-tagged proteins
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5697899A (en) 1995-02-07 1997-12-16 Gensia Feedback controlled drug delivery system
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5779708A (en) 1996-08-15 1998-07-14 Cyberdent, Inc. Intraosseous drug delivery device and method
CN1233291A (zh) * 1996-09-06 1999-10-27 宾西法尼亚大学托管会 重组腺伴随病毒定向基因治疗的方法
JP2001523959A (ja) 1997-04-21 2001-11-27 ユニバーシティ オブ フロリダ 疾患のリボザイム処置のための物質および方法
DE69939169D1 (de) * 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
CA2442670A1 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
CN1381579A (zh) * 2001-04-18 2002-11-27 上海博德基因开发有限公司 一种多肽——鸟苷酸环化酶－13.53和编码这种多肽的多核苷酸
US20030003582A1 (en) * 2001-05-08 2003-01-02 Tranzyme, Inc. Trans-viral vector mediated gene transfer to the retina
PT2573170T (pt) * 2001-12-17 2018-03-26 Univ Pennsylvania Sequências de um vírus adenoassociado (aav) de serotipo 9, vetor contendo as mesmas, e suas utilizações
WO2004065576A2 (en) * 2003-01-15 2004-08-05 Millennium Pharmaceuticals, Inc. Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
EP1616965A1 (en) * 2004-07-16 2006-01-18 AXXAM S.r.l. Methods and assays for detecting guanylate cyclase activity
WO2006036465A2 (en) 2004-09-03 2006-04-06 University Of Florida Compositions and methods for treating cystic fibrosis
US7943374B2 (en) * 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
WO2007078599A2 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
US8298818B2 (en) 2006-04-28 2012-10-30 University Of Florida Research Foundation, Inc. Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
KR20100061792A (ko) * 2007-10-01 2010-06-09 알콘 리서치, 리미티드 안 질환을 치료 또는 예방하기 위한 간섭 ｒｎａ 분자의 자기-상보적 ａａｖ 매개 전달
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
KR20190060881A (ko) 2019-06-03
SI2561067T1 (sl) 2019-04-30
LT2561067T (lt) 2019-03-12
DK3486320T3 (da) 2022-04-11
DK2561067T3 (en) 2019-03-11
MX2012012367A (es) 2012-11-16
CN105821079B (zh) 2021-10-26
WO2011133933A3 (en) 2012-01-05
HUE041571T2 (hu) 2019-05-28
MX351865B (es) 2017-10-30
HRP20190144T1 (hr) 2019-03-22
SG10201800541SA (en) 2018-03-28
EP2561067A2 (en) 2013-02-27
EP4056700A1 (en) 2022-09-14
CA2796399C (en) 2021-08-24
CN105821079A (zh) 2016-08-03
KR101984145B1 (ko) 2019-05-30
US20220186260A1 (en) 2022-06-16
RS58434B1 (sr) 2019-04-30
AU2011242527B2 (en) 2016-05-19
JP5897549B2 (ja) 2016-03-30
IL222651B (en) 2019-02-28
EP3486320A1 (en) 2019-05-22
JP2015091273A (ja) 2015-05-14
JP2019107037A (ja) 2019-07-04
CN102918152B (zh) 2016-04-13
JP2013526854A (ja) 2013-06-27
ES2711256T3 (es) 2019-04-30
EP2561067B1 (en) 2018-11-14
PT2561067T (pt) 2019-02-04
BR112012026730A8 (pt) 2018-07-03
TR201901377T4 (tr) 2019-02-21
JP2017114914A (ja) 2017-06-29
EA202091105A1 (ru) 2020-12-30
JP6533246B2 (ja) 2019-06-19
CO6640236A2 (es) 2013-03-22
SG184876A1 (en) 2012-11-29
SG10201913135YA (en) 2020-02-27
SMT201900097T1 (it) 2019-02-28
KR20130095643A (ko) 2013-08-28
NZ602897A (en) 2014-09-26
IL264649B (en) 2021-01-31
EA035893B1 (ru) 2020-08-27
BR112012026730A2 (pt) 2015-09-22
CL2012002969A1 (es) 2013-05-31
EA201291103A1 (ru) 2013-10-30
SG10201502759TA (en) 2015-06-29
IL222651A0 (en) 2012-12-31
CY1123008T1 (el) 2021-10-29
PL3486320T3 (pl) 2022-05-09
EP3486320B1 (en) 2022-01-19
US9816108B2 (en) 2017-11-14
KR20200047642A (ko) 2020-05-07
PT3486320T (pt) 2022-03-30
CA2796399A1 (en) 2011-10-27
CN102918152A (zh) 2013-02-06
WO2011133933A2 (en) 2011-10-27
US20180100165A1 (en) 2018-04-12
ES2911185T3 (es) 2022-05-18
US20130210895A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
PL2561067T3 (pl) Kompozycje RAAV-cyklazy guanylanowej i sposoby leczenia wrodzonej amaurozy-1 Lebera (LCA1)
IL253870A0 (en) Certain amino-pyrimidines, their assemblies, and methods of using them
IL249141A0 (en) Preparations for the treatment of parasites containing a large number of active factors, their methods and uses
PL2621277T3 (pl) Kompozycje fungicydowe
WO2011056650A9 (en) Methods and compositions for treating and preventing viral infections
BR112012016733A2 (pt) "composto, composição fungicida e método"
IL222465A0 (en) Certain amino-pyridazines, compositions thereof, and methods for their use
EP2581431A4 (en) AEROSOL COMPOSITION
IL223153A0 (en) Compositions comprising acid and derivatives thereof and uses thereof
PL2632550T3 (pl) Sposoby i kompozycja do leczenia biegunki związanej z HIV
PL2646520T3 (pl) Kompozycja na bazie 1,1,1,4,4,4-heksafluorobut-2-enu i 3,3,4,4,4-pentafluorobut-1-enu
WO2011137427A9 (en) Compositions and methods for treating pulmonary conditions
EP2563121A4 (en) PROCESS AND COMPOSITIONS FOR PROTECTION AGAINST NERVENGIFTS
FR2965705B1 (fr) Compositions d'edulcorants
HK1164745A (en) Methods and compositions for treating neuropathies
HK1174842A (en) Methods and compositions for treating degos' disease
FR2966151B1 (fr) Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
AU2011903807A0 (en) Disinfectant Compositions and Uses Thereof
IL212594A0 (en) Topical compositions containing coated active agents
FI8475U1 (fi) Jakelumuuntajan EMC-suojaus